CRISPR/Cas therapy helps lower "bad" cholesterol in familial hypercholesterolemia
Verve Therapeutics reported the results of clinical trials of VERVE-102, a drug for the treatment of genetic hypercholesterolemia. Its action is based on CRISPR/Cas technology. This technology was used to inactivate the defective gene and reduce cholesterol levels…